U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
NEWTOWN, Pa., Nov. 08, 2017 -- Helius Medical Technologies, Inc. (TSX:HSM), (OTCQB:HSDT) ("Helius" or the "Company"), a medical technology company focused on neurological wellness, announced today that it will report the results of its registrational trial investigating the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS™) for the treatment of chronic balance deficits due to mild-to-moderate Traumatic Brain Injury (TBI) by press release to be issued on Thursday, November 9, 2017 at 6:00 AM ET. The Company also plans to report results from a long-term clinical trial of the PoNS Therapy for the treatment of symptoms due to mild- to moderate TBI, performed at the University of Wisconsin-Madison.
Philippe Deschamps, the president and chief executive officer of Helius, will provide a presentation of the data, along with a company update, on Thursday, November 9, 2017 at 8:00 AM ET via webcast at http://www.wsw.com/webcast/cc/hsdt. Interested parties may also listen to the presentation by calling 1 (866) 939-3921 (US Toll Free) or 1 (678) 302-3550 (US Toll). Please use confirmation number 45986789. An archived copy of the webcast will be available at www.heliusmedical.com and http://www.wsw.com/webcast/cc/hsdt .
About PoNS™ Therapy
The Portable Neuromodulation Stimulator (PoNS™) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS™ Therapy combines the use of the device with physical therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate traumatic brain injury.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. Helius intends to file for FDA clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.
The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
HELIUS CONTACTS:
Investor Relations:
Josh Berg, 415-205-7891
[email protected]
Media Contact:
Becky Kern, 914-772-2310
[email protected]
